These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 12970106

  • 1. Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy.
    Schaerlinger B, Hickel P, Etienne N, Guesnier L, Maroteaux L.
    Br J Pharmacol; 2003 Sep; 140(2):277-84. PubMed ID: 12970106
    [Abstract] [Full Text] [Related]

  • 2. Dihydroergotamine and its metabolite, 8'-hydroxy-dihydroergotamine, as 5-HT1A receptor agonists in the rat brain.
    Hanoun N, Saurini F, Lanfumey L, Hamon M, Bourgoin S.
    Br J Pharmacol; 2003 May; 139(2):424-34. PubMed ID: 12770948
    [Abstract] [Full Text] [Related]

  • 3. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.
    Song J, Hanniford D, Doucette C, Graham E, Poole MF, Ting A, Sherf B, Harrington J, Brunden K, Stricker-Krongrad A.
    Assay Drug Dev Technol; 2005 Dec; 3(6):649-59. PubMed ID: 16438660
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
    Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M.
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Aug; 370(2):114-23. PubMed ID: 15322733
    [Abstract] [Full Text] [Related]

  • 5. The antimigraine drugs ergotamine and dihydroergotamine are potent 5-HT1C receptor agonists in piglet choroid plexus.
    Brown AM, Patch TL, Kaumann AJ.
    Br J Pharmacol; 1991 Sep; 104(1):45-8. PubMed ID: 1786517
    [Abstract] [Full Text] [Related]

  • 6. The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo.
    Beattie DT, Smith JA, Marquess D, Vickery RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N, Humphrey PP.
    Br J Pharmacol; 2004 Nov; 143(5):549-60. PubMed ID: 15466450
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Molecular pharmacology and ligand docking studies reveal a single amino acid difference between mouse and human serotonin 5-HT2A receptors that impacts behavioral translation of novel 4-phenyl-2-dimethylaminotetralin ligands.
    Canal CE, Cordova-Sintjago T, Liu Y, Kim MS, Morgan D, Booth RG.
    J Pharmacol Exp Ther; 2013 Dec; 347(3):705-16. PubMed ID: 24080681
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols.
    Cussac D, Newman-Tancredi A, Quentric Y, Carpentier N, Poissonnet G, Parmentier JG, Goldstein S, Millan MJ.
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Mar; 365(3):242-52. PubMed ID: 11882920
    [Abstract] [Full Text] [Related]

  • 13. Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503.
    Rosenzweig-Lipson S, Zhang J, Mazandarani H, Harrison BL, Sabb A, Sabalski J, Stack G, Welmaker G, Barrett JE, Dunlop J.
    Brain Res; 2006 Feb 16; 1073-1074():240-51. PubMed ID: 16430874
    [Abstract] [Full Text] [Related]

  • 14. [Effect of tropoxin on cerebrovascular effects of meta-chlorophenylpiperazine and serotonin].
    Gorbunov AA, Gan'shina TS, Mirzoian RS.
    Eksp Klin Farmakol; 2010 Sep 16; 73(9):13-6. PubMed ID: 21086646
    [Abstract] [Full Text] [Related]

  • 15. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells.
    Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I.
    Eur J Pharmacol; 2008 Oct 10; 594(1-3):32-8. PubMed ID: 18703043
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Predicted structures and dynamics for agonists and antagonists bound to serotonin 5-HT2B and 5-HT2C receptors.
    Kim SK, Li Y, Abrol R, Heo J, Goddard WA.
    J Chem Inf Model; 2011 Feb 28; 51(2):420-33. PubMed ID: 21299232
    [Abstract] [Full Text] [Related]

  • 18. Pharmacological actions of the main metabolites of dihydroergotamine.
    Müller-Schweinitzer E.
    Eur J Clin Pharmacol; 1984 Feb 28; 26(6):699-705. PubMed ID: 6489409
    [Abstract] [Full Text] [Related]

  • 19. Relatively slow and long-lasting antimigraine effect of dihydroergotamine is most likely due to basic pharmacological attributes of the drug: a review.
    Tfelt-Hansen PC.
    Cephalalgia; 2013 Oct 28; 33(13):1122-31. PubMed ID: 23588793
    [Abstract] [Full Text] [Related]

  • 20. Safety Pharmacology assessment of drugs with biased 5-HT(2B) receptor agonism mediating cardiac valvulopathy.
    Cavero I, Guillon JM.
    J Pharmacol Toxicol Methods; 2014 Oct 28; 69(2):150-61. PubMed ID: 24361689
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.